Cytosorbents (NASDAQ:CTSO) Announces Earnings Results

Posted by Francis Steltz on Aug 8th, 2026

Cytosorbents (NASDAQ:CTSO – Get Free Report) announced its earnings results on Thursday. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03), Zacks reports. The business had revenue of $9.63 million for the quarter, compared to analyst estimates of $9.38 million. Cytosorbents had a negative return on equity of 309.53% and a negative net margin of 48.94%.

Here are the key takeaways from Cytosorbents’ conference call:

Profitability and cash-burn trends improved: Second-quarter gross margin rose to 73%, adjusted EBITDA loss improved 38% year over year, and operating cash burn fell to approximately $200,000 excluding restructuring payments. Management reiterated its expectation of reaching operating cash-flow breakeven in the second half of 2026.
Revenue remained essentially flat at $9.6 million: Distributor and strategic-partner revenue increased 16% year over year and direct sales outside Germany rose 9%, offset by continued weakness in Germany and Middle East disruptions. The company plans to add three to five German sales representatives through early 2027.
DrugSorb-ATR still faces regulatory uncertainty: The FDA previously denied the company’s de novo application because the pivotal STAR-T trial missed its primary endpoint, although management said a new clinical trial is not required. Cytosorbents plans to submit additional mechanistic data and real-world evidence, with separate FDA discussions planned for the ticagrelor and DOAC indications.
Management highlighted favorable DrugSorb-ATR secondary analyses: In the CABG per-protocol population, the severe-bleeding endpoint achieved a statistically significant win ratio of 1.59, while a composite of severe bleeding or more than one liter of chest-tube blood loss showed a reported 58% relative risk reduction. These analyses may support a renewed FDA submission, though they do not eliminate the prior primary-endpoint miss.
HemoDefend-BGA represents longer-term strategic optionality rather than current revenue: The universal-plasma technology has completed development and received constructive FDA feedback on a potential clinical pathway, but Cytosorbents does not plan to fund clinical trials from its current resources. Progress depends on government funding, partnerships, licensing, or another strategic transaction.

Cytosorbents Price Performance

Shares of Cytosorbents stock traded down $0.04 on Friday, reaching $0.36. 96,364 shares of the stock were exchanged, compared to its average volume of 61,883. The firm’s 50 day moving average is $0.40 and its 200-day moving average is $0.55. Cytosorbents has a one year low of $0.35 and a one year high of $1.22. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $22.62 million, a PE ratio of -1.24 and a beta of 1.39.

Insider Transactions at Cytosorbents

In other news, CEO Phillip P. Chan acquired 251,136 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average cost of $0.40 per share, with a total value of $100,454.40. Following the completion of the purchase, the chief executive officer directly owned 1,734,099 shares of the company’s stock, valued at $693,639.60. The trade was a 16.93% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cytosorbents

Large investors have recently modified their holdings of the business. Citadel Advisors LLC raised its holdings in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after buying an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in Cytosorbents in the third quarter valued at about $161,000. Vanguard Group Inc. grew its position in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Finally, Avenir Corp raised its stake in Cytosorbents by 2.9% during the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after acquiring an additional 147,261 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cytosorbents presently has an average rating of “Hold” and a consensus price target of $5.38.

Check Out Our Latest Research Report on CTSO

About Cytosorbents

(Get Free Report)

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.